Biosimilars
Clinical Trials
Samsung Bioepis Reports Results of SB11 (proposed biosimilar ranibizumab) in
Shots: The P-III study involves assessing of SB11 vs reference product, LUCENTIS in monthly injections (0.5mg) in 705 patients in a ratio (1:1) with nAMD The P-III study results demonstrated equivalent efficacy in terms of change in BCVA @8wk. and CST @4wk., LS change in BCVA (6.2 vs 7.0 letters), LS change in CST ( […]Read More
